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Abstract
Background: To allow an accurate evaluation of abstracts of systematic reviews, the PRISMA Statement
recommends that the limitations of the evidence (e.g., risk of bias, publication bias, inconsistency, imprecision)
should be described in the abstract. We aimed to evaluate the impact of adding such limitations sections on
reader’s interpretation.
Method: We performed a two-arm parallel group randomized controlled trial (RCT) using a sample of 30 abstracts
of systematic reviews evaluating the effects of healthcare intervention with conclusions favoring the beneficial effect
of the experimental treatments. Two formats of these abstracts were derived: one reported without and one with a
standardized limitations section written according to the PRISMA statement for abstracts. The primary outcome was
readers’ confidence in the results of the systematic review as stated in the abstract assessed by a Likert scale from
0, not at all confident, to 10, very confident. In total, 300 participants (corresponding authors of RCT reports indexed
in PubMed) were randomized by a web-based randomization procedure to interpret one abstract with a limitations
section (n = 150) or without a limitations section (n = 150). Participants were blinded to the study hypothesis.
Results: Adding a limitations section did not modify readers’ interpretation of findings in terms of confidence in
the results (mean difference [95% confidence interval] 0.19 [−0.37–0.74], p = 0.50), confidence in the validity of the
conclusions (0.07 [−0.49–0.62], p = 0.80), or benefit of the experimental intervention (0.12 [−0.42–0.44], p = 0.65).
This study is limited because the participants were expert-readers and are not representative of all systematic review
readers.
Conclusion: Adding a limitations section to abstracts of systematic reviews did not affect readers’ interpretation of
the abstract results. Other studies are needed to confirm the results and explore the impact of a limitations section
on a less expert panel of participants.
Trial registration: ClinicalTrial.gov (NCT01848782).
Keywords: Meta-analysis, Systematic review, Bias, Limits, Limitation, Interpretation, Interpretation bias,
Misinterpretation, Abstract, Results
* Correspondence: ayavchitz@gmail.com
1Centre de Recherche Épidémiologies et Statistiques INSERM U1153,
Paris, France
2Centre of Clinical Epidemiology, Assistance Publique des Hôpitaux de Paris,
Hôtel Dieu Hospital, Place du Parvis Notre-Dame, 75181 Paris, Cedex 4, France
Full list of author information is available at the end of the article
© 2014 Yavchitz et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Yavchitz et al. BMC Medical Research Methodology 2014, 14:123
http://www.biomedcentral.com/1471-2288/14/123
Background
Systematic reviews are the cornerstone of therapeutic
evaluation [1]. Clinicians, decision makers and researchers
use them to keep up-to-date with current medical litera-
ture, develop clinical practice guidelines and sometimes
plan future research [2-4]. However, systematic reviews
may differ in quality depending on the conduct of the sys-
tematic review as well as the availability and quality of the
primary studies [5]. Consequently, readers should carefully
examine the methodological quality of reviews to assess
their confidence in the results and conclusions.
Clinical decision makers and healthcare practitioners
frequently rely on abstracts to decide the value of a study
[6,7]. In some cases, healthcare practitioners have access
to only the abstract and make healthcare decisions based
solely on the information in the abstract [8]. To improve
the transparency of abstracts [9,10], methodologists, re-
searchers and editors have established recommendations
for the presentation of systematic reviews in the PRISMA
statements [11] with an extension for reporting abstracts
[12]. These recommendations indicate that the limitations
of the evidence should be described in the abstracts of
systematic reviews [12]. This recommendation is rarely
implemented [13], although some journals request that
authors report a structured abstract with a limitations
section [14]. However, the impact of adding this section
to abstracts on readers’ interpretation is unknown.
We aimed to evaluate the impact of adding a limitations
section, written according to the PRISMA statement for
abstracts of systematic reviews, on readers’ interpretation
of the abstract results.
Methods
Study design
We planned a randomized controlled trial to compare
the interpretation of systematic review abstracts reported
with and without a limitations section. We selected 30
abstracts of systematic reviews, and then developed 2
formats of the selected abstracts: reported with and with-
out a limitations section written according to the PRISMA
statement for abstracts. Then, we randomized participants
to read and interpret one abstract with or without a limi-
tations section. The study reporting follows the 2010
CONSORT statement [15].
Selection of abstracts of systematic reviews
The abstracts were selected from a cohort of 100 system-
atic reviews assessing the effects of healthcare interven-
tions, published between January and March 2012, and
indexed in the Database of Reviews of Effects [13]. The
search strategy and eligibility criteria for this cohort were
described elsewhere [13]. From this cohort, we selected
the first 30 systematic reviews whose abstract conclu-
sion favored the beneficial effect of the experimental
intervention and reported the risk of bias of primary
studies in the full-text article, thus allowing selection
of a relatively homogeneous sample. Abstracts from
the cohort of 100 systematic reviews were screened by
one author (AY) and reviewed by a second author (IB)
to confirm eligibility. Any disagreements were resolved
by consensus.
Construction of the limitations section
According to the PRISMA statement for abstracts, the
limitations section should address the following: 1) risk of
bias common to many or all studies, such as lack of
blinding for subjective outcomes or unavailability of
data; 2) inconsistency of effect or association, as dem-
onstrated by high heterogeneity; 3) imprecision due to
few events or small sample size, for example; 4) indir-
ectness of the evidence, such as use of an intermediate
or short-term outcome; and 5) likelihood of publica-
tion bias [12,16]. These limitations are the factors used
to evaluate the level of evidence according to the GRADE
approach [17].
One author (AY) systematically searched for and ex-
tracted from the full-text systematic review the follow-
ing: 1) whether the systematic review had one or several
of the limitations described above and 2) the limitations
were reported by the authors of the systematic review in
the full-text article or in the abstract. When limitations
were outcome-specific, the limitations reported referred
to the outcomes highlighted in the abstracts.
Then, for each selected abstract, one of the authors
(AY) wrote a limitations section. The section focused on
the limitations identified and was written in a standard-
ized way, beginning with “This review is limited by….”,
with a maximum of 2 sentences. When the original ab-
stract was structured, we preserved the structured form
and added the limitations section before the conclusions
section with a heading “Limitations”. When the original
abstract was not structured, we added the limitations
section, without a heading, after the results and before the
conclusion sentences.
We voluntarily did not use the same terminology as
PRISMA because it may not be well understood by the
readers (e.g., imprecision, inconsistency of effect or asso-
ciation and indirectness of the evidence are complex
concepts). We kept the wording similar to that used by
the authors of the systematic reviews, for example, when
reporting the limitations in the discussion section. An-
other author (IB) read the entire modified abstract to de-
termine whether the limitations section was written
according to our specific guidance, that is, whether the
limitations section 1) focused on the limitations previously
identified in the report of the systematic review, 2) was no
longer than 2 sentences, and 3) focused on limitations as
described in the PRISMA for abstracts. When the second
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author found that the limitation section was not written
according our specific guidance, the limitations section
was re-written and discussed to reach consensus.
Construction of abstracts with and without a limitations
section
For each of the 30 selected abstracts, we obtained 1 ab-
stract without a limitations section (i.e., the original ab-
stract) and 1 with a limitations section (i.e., the original
abstract plus the constructed limitations section). If the
original abstract reported the limitations of the systematic
review, this was deleted from the abstract without a limi-
tations section and kept in the abstract with a limitations
section. This situation occurred for 9 (30%) abstracts.
All abstracts were standardized, with the treatment name
(s), authors and journal masked. The experimental treat-
ment name was replaced by “intervention A”. When the
control treatment was an active treatment, “comparator B”
replaced the treatment name. Acronyms and abbreviations
were also deleted.
An example of an abstract with and without a limita-
tions section is given in the Table 1 and all abstracts with
a limitations section are available in the Additional file 1.
Participants
Eligible participants were the corresponding authors of
clinical trials published between January 2010 and June
2013 and indexed in PubMed Core Clinical Journals,
with an email address available on PubMed.
Potential participants were invited by e-mail to partici-
pate in an online survey on the interpretation of abstracts
of systematic reviews. As an incentive, they were told that
they would be entered into a draw along with all other
participants for a chance to win an Apple iPad mini. If
they agreed to participate, they logged onto a secure web-
site and answered a screening question asking if they were
a clinician; non-clinicians were excluded. Invitation emails
were sent in waves until the planned number of clinicians
had logged on and completed the assessment. A max-
imum of 2 reminders were sent to participants. The email
invitation and details of the questionnaire are in the
Additional file 1.
Randomization
A computer-generated randomization list was generated
for allocating participants to abstracts with or without a
limitations section in a 1:1 ratio. Allocation was con-
cealed by use of a web-based randomization procedure
whereby participants logged onto the system and were
randomized to evaluate an abstract with or without a
limitations section. Clinicians who logged onto the sys-
tem but did not evaluate an abstract were excluded
and the abstract was automatically allocated to another
clinician.
Table 1 Example of abstract construction
Abstract without limitations section Abstract with limitations section
TITLE: Comparative effectiveness of intervention A and comparator B for
treatment of advanced urothelial carcinoma.
TITLE: Comparative effectiveness of intervention A and comparator B for
treatment of advanced urothelial carcinoma.
BACKGROUND: Intervention A is a standard treatment of metastatic
urothelial carcinoma (UC), though comparator B is frequently substituted
due to improved tolerability. Because comparative effectiveness in clinical
outcomes of intervention A - versus comparator B chemotherapy is lacking,
a meta-analysis was carried out.
BACKGROUND: Intervention A is a standard treatment of metastatic
urothelial carcinoma (UC), though comparator B is frequently substituted
due to improved tolerability. Because comparative effectiveness in clinical
outcomes of intervention A - versus comparator B chemotherapy is lacking,
a meta-analysis was carried out.
METHODS: PubMed was searched for articles published from 1966 to
2010. Eligible studies included prospective randomized trials evaluating
intervention A - versus comparator B regimens in patients with metastatic
UC. Individual patient data were not available and survival data were
inconsistently reported. Therefore, the analysis focused on overall response
(OR) and complete response (CR) rates. The Mantel-Haenszel method was
used for combining trials and calculating pooled risk ratios (RRs).
METHODS: PubMed was searched for articles published from 1966 to
2010. Eligible studies included prospective randomized trials evaluating
intervention A - versus comparator B regimens in patients with metastatic
UC. Individual patient data were not available and survival data were
inconsistently reported. Therefore, the analysis focused on overall response
(OR) and complete response (CR) rates. The Mantel-Haenszel method was
used for combining trials and calculating pooled risk ratios (RRs).
RESULTS: A total of 286 patients with metastatic UC from four
randomized trials were included. Intervention A was associated with a
significantly higher likelihood of achieving a CR [RR =3.54; 95%
confidence interval (CI) 1.48-8.49; P =0.005] and OR (RR =1.34; 95% CI
1.04-1.71; P =0.02). Survival end points could not be adequately assessed
due to inconsistent reporting among trials.
RESULTS: A total of 286 patients with metastatic UC from four
randomized trials were included. Intervention A was associated with a
significantly higher likelihood of achieving a CR [RR =3.54; 95%
confidence interval (CI) 1.48-8.49; P =0.005] and OR (RR =1.34; 95% CI
1.04-1.71; P =0.02). Survival end points could not be adequately assessed
due to inconsistent reporting among trials.
CONCLUSIONS: Intervention A, as compared with comparator B,
significantly increases the likelihood of both OR and CR in patients with
metastatic UC. The impact of improved response proportions on survival
end points could not be assessed.
LIMITATIONS: This review is limited by the small sample sizes and
methodological quality of the included studies. None of the included
studies was blinded or placebo controlled; two studies closed early.
Conclusions: Intervention A, as compared with comparator B,
significantly increases the likelihood of both OR and CR in patients with
metastatic UC. The impact of improved response proportions on survival
end points could not be assessed.
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Blinding
Participants were blinded to the study’s hypothesis. They
were informed that they were participating in a study on
the interpretation of abstracts of systematic reviews, but
they were not aware that they were randomized to assess
an abstract with or without a limitations section.
Outcomes measures
The primary outcome was readers’ confidence in the
results of the systematic review as stated in the abstract
(i.e., How confident are you in the results of the systematic
review?) assessed on a Likert scale, from 0 “not at all
confident” to 10 “very confident”. The secondary out-
comes were the confidence in the validity of the con-
clusions (i.e., How confident are you in the validity of
the conclusion of this study?), the beneficial effect of
the experimental intervention (i.e., How confident are
you that intervention “A” could be of benefit to patients?),
the influence of the results on clinical practice (i.e., How
confident are you that the results of this study could influ-
ence your clinical practice?) and the rigor of the systematic
review (i.e., Do you think that this systematic review
was conducted rigorously?) assessed on an 11-point
Likert scale.
Sample size
Each participant read 1 abstract with or 1 abstract with-
out a limitations section. The unit of analysis was the
abstract. A sample of 266 participants was theoretically
needed to be able to detect an effect size of 0.4 with the
primary outcome (with power of 90% and alpha risk
5%). An effect size of 0.4 is equivalent to a decrease in
the primary outcome of 1 point (the minimum expected
difference between groups on a 0–10 scale) with an SD
of 2.5. Theoretically, each abstract must be read the
same number of times according to the randomization
group. Knowing that each participant would read only
one abstract (with or without a limitations section), we
chose to include 300 participants. Each abstract with
and without a limitations section was assessed 5 times.
Statistical analysis
Statistical analysis involved use of SAS v9.3 (SAS Inc.,
Cary, NC). All outcomes were quantitative; differences
between groups were analyzed by a linear mixed model
with a fixed factor (group) and random abstracts and ab-
stract × group interaction effects. A random-effects model
allowed for taking into account 2 levels of clustering: by
abstract (each abstract was assessed 5 times in each group)
and interclustering (pairing between the abstracts used in
the 2 arms of the trial). Inference was based on restricted
maximum likelihood. For primary outcome and secondary
outcomes, we estimated the difference between means
(with 95% confidence intervals [95% CIs]) for abstracts
with and without a limitations section. P <0.05 was
considered statistically significant.
Ethical considerations
The institutional review board from the University of Paris
Descartes approved the protocol No. CL178200001. The
study is registered in ClinicalTrials.gov (no. NCT01848782).
Results
Characteristics of participants
Among the 4,807 potential participants who were invited
by e-mail to participate in the survey between May 1
and June 30, 2013, 394 logged onto the study site; 89
were excluded because they were not clinicians and 5
did not complete the survey. From the 300 participants,
150 were randomized to the intervention group (i.e., ab-
stracts with a limitations section), and 150 to the control
group (i.e., abstracts without a limitations section). In total,
150 participants per group were included in the final ana-
lysis (Figure 1).
The median [Q1-Q3] participant age was 45 [range
38–54] years; 72% were male. Participants were mainly
located in the European Union (49%) and in the
United States (33%). Most had medical experience
(74.7% had been clinicians for more than 10 years)
and more than half (59%) regularly read reports of sys-
tematic reviews. More than half (53%) had been in-
volved in a systematic review, but 46% had never peer-
reviewed a systematic review for a biomedical journal
(Table 2).
Characteristics of systematic reviews, abstracts and
limitations sections
The general characteristics of the included systematic
reviews and the quality of the reporting of the abstracts
(according to the PRSIMA statement for abstracts [12])
are in Table 3.
Overall, 23 abstracts were structured abstracts, and we
created a specific heading for the limitations section,
whereas 7 abstracts were not structured, and a sen-
tence reporting the limitations was added before the
conclusions. Some limitations were reported in 9 ori-
ginal abstracts. These limitations were deleted and
rewritten according to the PRISMA guidelines. The
quality assessment of the risk of bias in the selected
systematic reviews was assessed with different tools.
Authors of the included systematic reviews used the
Cochrane or a modified Cochrane Collaboration tool
in 10 abstracts (33%), the Jadad scale or modified Jadad
scale in 5 (17%), the PEDro scale or modified PEDro
scale in 3 (10%), and other tools in 4 (13%); the scale
was not specified in 6 (20%).
The limitations sections we created focused on risk of
bias in 22 abstracts (73%), heterogeneity in 13 (43%),
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publication bias in 15 (50%), imprecision of results in 12
(40%), and indirectness of the evidence in 2 (7%) abstracts.
The median [Q1-Q3] word count for limitations sections
was 27 [23–31]. The median number of limits described
in the limitations sections was 2 (range 1–4).
Clinicians’ interpretation of abstracts
Readers’ assessment of abstracts with and without a lim-
itations section did not differ in the primary outcome –
confidence in the results (mean [SD] =4.4 [2.3] and 4.6
[2.5], respectively; mean difference [95% CI] 0.2 [−0.4 to
0.7], p = 0.5). For the secondary outcomes, the assess-
ment of abstracts with and without a limitations section
did not differ for confidence in the validity of the conclu-
sions (mean difference 0.07 [−0.5 to 0.6], p = 0.8); benefit
of the experimental intervention to patients (mean differ-
ence 0.1 [−0.4 to 0.7], p = 0.6); influence of the results
on clinical practice (mean difference −0.08 [−0.6 to 0.5],
p = 0.8) and rigor of the systematic review (mean difference
−0.4 [−1.0 to 0.2], p = 0.2) (Table 4).
Discussion
This study evaluated, in a randomized controlled trial,
the impact of adding a limitations section to an abstract
on the interpretation of abstracts of systematic reviews.
This randomized controlled trial involved a large inter-
national sample of clinicians and a sample of “real life”
abstracts of systematic reviews (i.e., abstracts of pub-
lished systematic reviews indexed in DARE). Despite the
selection of a sample of systematic reviews of good qual-
ity, the mean confidence of readers was low, and adding
a limitations section had no impact on the interpretation
of abstract results by expert-readers.
Because abstracts are the first and sometimes the only
source of information for readers, editors are attentive
to their quality and their capacity to provide all the ne-
cessary and important information on the research per-
formed. In the 1960s, abstracts were usually reported on
the last page of research articles and were moved to the
beginning of research articles [18]. Since then, many edi-
torial policies have been implemented to try to improve
the content and the format of abstracts. These policies
Figure 1 Flow chart of participants in the trial.
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have involved the development and implementation of
structured abstracts [18,19], reporting guidelines such as
the CONSORT for abstracts of randomized controlled
trials and the PRISMA statement for abstracts of sys-
tematic reviews [12,20]. Such policies can improve the
quality of reporting of abstracts [21] and should in the-
ory improve the interpretation by readers.
However, despite these initiatives, the quality of reporting
of abstracts remains questionable [9,10,22-24]. A recent
study showed that despite systematic reviews including pri-
mary studies with high risk of bias, just over half included
a risk of bias assessment in the interpretation of results in
the abstract [13]. Consequently, adding a limitations sec-
tion could be useful to enhance readers’ awareness and
improve their interpretation. However, a limitations sec-
tion in the abstract is recommended by only a few journals
and for systematic reviews in the PRISMA statement for
abstracts [12]. For example, Annals of Internal Medicine
has required authors to include a limitations section in
the abstract of scientific articles since 2004 [14].
To our knowledge, the impact of adding a limitations
section in abstracts of systematic reviews has never been
evaluated. Previous studies have evaluated the impact
of different reporting on the interpretation of the study
by readers. These studies mainly involved use of a sin-
gle abstract of a fictional trial. For example, industry
sponsorship can negatively influence the perception of
the methodological quality of a study and the willingness
to believe the study findings [25]. Similarly, interpret-
ation of study results is affected by the reporting of out-
comes as absolute risk, relative risk or number needed
to treat [26,27].
Our results did not show any impact of the abstract
limitations section on expert-readers’ interpretation. Fur-
thermore, our results highlight that confidence in results
was low in both arms. The high level of expertise of the
participants could explain these results. In fact, half of
the clinicians included in this randomized controlled
trial had some experience in the conduct and reviewing
of systematic reviews. This level of expertise could in-
crease their awareness of the common limitations of sys-
tematic reviews such as the risk of publication bias or
the limited quality of primary studies. Furthermore, the
limitations section reported factual information and in a
neutral form, and the conclusion of the systematic re-
views’ abstract was not modified. Also, assessing the
confidence in the results of a systematic review is com-
plex because it depends both on how the systematic re-
view is conducted and the quality of the primary studies
included.
Our study has some limitations. First, the readers did
not access the full-text article to fully appraise the study
results; they only assessed an abstract with or without a
limitations section. However abstracts of systematic re-
views are very important, because some readers cannot
access full-text articles because of the fee requirement,






N = 150 N = 150 N = 300
Qualification MD 78 (52.0) 78 (52.0) 156 (52.0)
PhD 58 (38.7) 64 (42.7) 122 (40.7)
Other 14 (9.3) 8 (5.3) 22 (7.3)
Clinical experience <5 years 6 (4.0) 8 (5.3) 14 (4.7)
5 to 10 years 34 (22.7) 28 (18.7) 62 (20.7)
>10 years 110 (73.3) 114 (76.6) 224 (74.7)
Reading reports of systematic reviews Rarely or sometimes 61 (40.7) 62 (41.6) 123 (41.1)
Regularly 89 (59.3) 87 (58.4) 176 (58.9)
No. of randomized trials involved in 0 16 (10.7) 11 (7.3) 27 (9.0)
1–3 48 (32.0) 48 (32.0) 96 (32.0)
4–9 45 (30) 54 (36.0) 99 (33.0)
>10 41 (27.3) 37 (24.7) 78 (26.0)
Authored at least one systematic review 77 (51.3) 82 (55.0) 159 (53.2)
No. of systematic reviews peer-reviewed 0 75 (50.0) 64 (43.0) 139 (46.5)
1–3 55 (36.7) 69 (46.3) 124 (41.5)
>3 20 (13.3) 16 (10.7) 36 (12.0)
Training in clinical epidemiology 101 (67.3) 76 (50.7) 177 (59.0)
Training in methods of randomized trials 86 (57.3) 71 (47.3) 157 (52.3)
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low Internet download capacity, or the full-text article
being available only in a language not understood by the
reader. Second, the participants were corresponding au-
thors of articles of randomized trials and systematic re-
views, who may be considered “reader-experts” and not
representative of all readers of systematic reviews. Con-
sequently, we cannot exclude that a limitations section
may be useful for a less expert readership. Finally, we ex-
plored only the impact of a limitations section added to
abstracts reporting a systematic review and we cannot
extrapolate our findings to limitations sections in abstracts
reporting other types of studies such as randomized con-
trolled trials and observational studies.
However, this study has important implications. At
this stage, we cannot make any recommendations for
practice and we should probably not change guidelines
and editorial policies related to the reporting of a limi-
tations section in abstracts of systematic reviews. How-
ever, this study highlights an important topic for future
research. First, because our study is the first study on
Table 3 Characteristics of systematic reviews included
Characteristics N = 30
Field of research, n (%) Medicine 27 (90)
Surgery 3 (10)
Impact factor, median; [Q1-Q3]; (min-max) 4.60; [3.18–7.51]; (0.00-18.04)
No. of trials included, median; [Q1-Q3];
(min-max)
13; [6–23]; (4–54)
Sample size, median; [Q1-Q3]; (min-max) 2872; [801–11005]; (257–782460)
Experimental treatment, n (%) Drugs 16 (53)
Complex intervention 11 (37)
Surgery 2 (7)
Device 1 (3)
Meta-analysis included in the systematic
review, n (%)
26 (87)
Funding source, n (%) Non-profit 11 (37)
For-profit 2 (7)
None 10 (33)
Not specified 7 ((23)
Content of the original abstract, n (%) Eligibility criteria 17 (57%)
Key data bases and date of search 9 (30%)
Method to assess the risk of bias 6 (20%)
No. and type of the studies included in the systematic review 22 (73%)
Summary measure and confidence interval
for the main outcome results*
20/26 (77%)
Strength and limitation 13 (43%)
*This result applies on the 26 systematic reviews that included a meta-analysis.
Table 4 Results of primary and secondary outcomes
Abstract without limitations With Limitations Mean difference
(95% CI)
p-value
Mean (SD) n = 150 Mean (SD) n = 150
How confident are you in the results of this study (0–10)? 4.6 (2.5) 4.4 (2.3) 0.2 (−0.4 to 0.7) p =0.5
How confident are you in the validity of the conclusion
of this study (0–10)?
4.1 (2.5) 4.0 (2.3) 0.07 (−0.5 to 0.6) p =0.8
How confident are you that the intervention A could be
benefit to patients (0–10)?
4.4 (2.6) 4.3 (2.3) 0.1 (−0.4 to 0.7) p =0.6
How confident are you that the results of this study
could influence your clinical practice (0–10)?
3.8 (2.6) 3.8 (2.3) −0.08 (−0.6 to 0.5) p =0.8
Do you think that this systematic review was conducted
rigorously (0–10)?
4.1 (2.7) 4.4 (2.6) −0.4 (−1.0 to 0.2) p =0.2
95% CI, 95% confidence interval.
Yavchitz et al. BMC Medical Research Methodology 2014, 14:123 Page 7 of 9
http://www.biomedcentral.com/1471-2288/14/123
this topic, the trial should be replicated, and other trials
including a less expert readership or with different back-
ground (e.g. authors of “clinical practice guidelines”)
should be performed. Second, qualitative studies would
probably be useful to help define how limitations sections
should be reported to have a real impact on readers.
Third, we recommend exploring the impact of a limita-
tions section in abstracts of other study designs such as
randomized controlled trials and observational studies.
Overall, more research is needed on the interpretation of
research results from abstracts because abstracts are widely
disseminated.
Conclusions
In conclusion, adding a limitations section in abstracts
of systematic review may not affect expert-readers’ inter-
pretation of abstract results and conclusions. Future studies
are needed to confirm these results and explore the impact
of a limitations section on a less expert panel of participants.
Additional file
Additional file 1: The 30 Abstracts with limitations section. The
invitation e-mail for the participants. The survey.
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